KYNB compared with TMCI: revenue, margins and what each company keeps, and the suppliers and customers both name

KYNBKyntra Bio, Inc.

Mkt capRevenueRevenue

TMCITreace Medical Concepts, Inc.

Mkt capRevenueRevenue

Compare

KYNBKyntra Bio, Inc.

TMCITreace Medical Concepts, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KYNB: latest quarter is a loss; flow not drawable. TMCI: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

KYNB, solidTMCI, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KYNB 10

AZNAstraZeneca AB ("AstraZeneca")customer

—Astellas Pharma Inc. ("Astellas")unlistedsupplier

—Fortis Therapeutics, Inc. ("Fortis")unlistedsupplier

—Shanghai SynTheAll Pharmaceutical Co., Ltd. ("WuXi STA")unlistedsupplier

6 more · KYNB chain ›

Shared 0

No shared counterparties.

Only TMCI 1

—MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D")unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

KYNBKyntra Bio, Inc.

4.15▼−3.71%· post 4.15

Mkt cap$16.0MRevenue$4MQ1 FY26Revenue$6MFY25

TMCITreace Medical Concepts, Inc.

4.28▼−0.02%· post 4.50

ClosedNov 4 '26

Mkt cap$292.7MRevenue$45MQ2 FY26Revenue$213MFY25

Compare

ClosedNov 4 '26

KYNBKyntra Bio, Inc.

TMCITreace Medical Concepts, Inc.

4.15▼−3.71%post 4.15

Price

4.28▼−0.02%post 4.50

$16.0M

Mkt cap

$292.7M

Q1 FY26$4M

Revenue

$45MQ2 FY26

FY25$6M

Revenue

$213MFY25

KYNB4.15▼−3.71%vsTMCI4.28▼−0.02%ClosedNov 4 '26